C3orf62 and neoplasm: From a therapeutic viewpoint, selective targeting of MAPs while leaving the bulk of cellular proteasomes untouched may be effective in suppressing tumor growth and viral propagation with much-reduced side effects associated with common proteasome inhibitors.